SCHEMBL4373619

SCHEMBL4373619

CN1CCc2c(-c3ccccc3)cc3c(c2C1)NC(=O)/C3=N\O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
GRIA4 P48058 1/20 0.37
CYP2C9 P11712 1/20 0.36
MAPT P10636 5/20 0.35
KDM4E B2RXH2 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
SLC2A1 P11166 1/20 0.33
CDYL Q9Y232 2/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TNKS O95271 1/20 0.33
PARP1 P09874 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373620 1.00 GRIA1 (0.37) GRIA1GRIA2GRIA3GRIA4CYP2C9
SCHEMBL8114854 0.96 CYP2C9 (0.36) GRIA1GRIA2GRIA3GRIA4CYP2C9
SCHEMBL8114848 0.96 CYP2C9 (0.36) GRIA1GRIA2GRIA3GRIA4CYP2C9
SCHEMBL4373864 0.91 MAPK14 (0.32) MAPTKDM4EALDH1A1TNKSPARP1
SCHEMBL14287160 0.90 CYP2C9 (0.36) GRIA1GRIA2GRIA3GRIA4CYP2C9
SCHEMBL14287107 0.89 PRKCA (0.36) GRIA1GRIA2GRIA3GRIA4MAPT
SCHEMBL14287092 0.89 TDP2 (0.35) GRIA1GRIA2GRIA3GRIA4MAPT
SCHEMBL13592439 0.89 GRIA1 (0.38) GRIA1GRIA2GRIA3GRIA4GAA
SCHEMBL8103012 0.89 MEN1 (0.38) GRIA1GRIA2GRIA3GRIA4CYP2C9
SCHEMBL13592447 0.89 GRIA1 (0.38) GRIA1GRIA2GRIA3GRIA4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1736468-A2 Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation NeuroSearch A/S (DK) 2006-12-27 EP claimed
US-20060229311-A1 Isatine derivatives with neurotrophic activity GROENBORG METTE 2006-10-12 US claimed
US-20030040518-A1 Isatine derivatives with neurotrophic activity ANIONA APS (DK) 2003-02-27 US claimed
US-7595336-B2 Isatine derivatives with neurotrophic activity NEUROSEARCH A/S (DK) 2009-09-29 US disclosed
US-7282511-B2 Isatine derivatives with neurotrophic activity NEUROSEARCH A/S (DK) 2007-10-16 US disclosed
EP-1736468-A2 Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation NeuroSearch A/S (DK) 2006-12-27 EP disclosed
US-20060229311-A1 Isatine derivatives with neurotrophic activity GROENBORG METTE 2006-10-12 US disclosed
US-20030040518-A1 Isatine derivatives with neurotrophic activity ANIONA APS (DK) 2003-02-27 US disclosed
EP-0781284-B1 INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH AS (DK) 2000-01-12 EP disclosed
EP-0698025-B1 AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH NEUROSEARCH AS (DK) 1997-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229311-A1 Isatine derivatives with neurotrophic activity BDNF, NTRK2, NGF GRIA1 2063/4885GRIA2 1785/4885GRIA3 653/4885
US-20030040518-A1 Isatine derivatives with neurotrophic activity BDNF, NTRK2, NGF GRIA1 2063/4885GRIA2 1785/4885GRIA3 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.